Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502 Attar, Eyal C. , Johnson, Jeffrey L. , Amrein, Philip C. ... - - J. Clin. Oncol. - 2013 Manuscript - Primary - Primary - Leukemia - CALGB-10502
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance) Roboz, Gail J. , Mandrekar, Sumithra J. , Desai, Pinkal ... - - Blood Adv - 2018 Manuscript - Primary - Primary - Leukemia - CALGB-11002
Allogeneic Hematopoietic Cell Transplantation Compared to Chemotherapy Consolidation in older Acute Myeloid Leukemia (AML) Patients 60–75 Years in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study Ustun, Celalettin , Le-Rademacher, Jennifer , Wang, Hai-Lin ... - - Leukemia - 2019 Manuscript - Primary - Primary - Older Adult - A151509 , CALGB-10502 , CALGB-10801 , CALGB-11001 , CALGB-11002 , E3999 , S0432 , S0703
